S. Harrison
Epidemiology · Hepatology · 2003–2023
A researcher in the Science corpus: 14 papers; trusts 1 researcher and is trusted by 6 researchers here, as inferred from the citation graph.
Subfields
- Epidemiology — 184 citations into it; #637 of 2,148 by trust here, #155 by citations
- Pathology and Forensic Medicine — 32 citations into it
Whom S. Harrison trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Who trusts S. Harrison overall
- Z. Younossi
- N. Chalasani
- Vincent Wai-Sun Wong
- K. Cusi
- V. Ratziu
- G. Targher
- Asociacion Latinoamericana para el Estudio del Higado
- M. Rinella
Papers from S. Harrison's perspective
Ordered by how strongly the researchers S. Harrison trusts endorse each paper. Same corpus, a different order for every researcher.
- ENDPOINTS AND CLINICAL TRIAL DESIGN FOR NONALCOHOLIC STEATOHEPATITIS (Hepatology)
- Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. (Gastroenterology)
- Pathologic criteria for nonalcoholic steatohepatitis: Interprotocol agreement and ability to predict liver‐related mortality (Hepatology)
- The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the… (American Journal of Gastroenterology)
- The prevalence and etiology of elevated aminotransferase levels in the United States (American Journal of Gastroenterology)
- Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome (Hepatology)
- Meta‐analysis of the influence of I148M variant of patatin‐like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease (Hepatology)
- Liver Fibrosis, but no Other Histologic Features, Associates with Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease (Gastroenterology)
- Histopathology of pediatric nonalcoholic fatty liver disease (Hepatology)
- Meta-analysis: Natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity (Annals medicus)
Their papers
- A multisociety Delphi consensus statement on new fatty liver disease nomenclature (2023) — 2,276 citations
- A multi-society Delphi consensus statement on new fatty liver disease nomenclature. (2023) — 2,621 citations
- FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study (2020) — 638 citations
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. (2020) — 1,488 citations
- Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. (2019) — 1,024 citations
- Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. (2019) — 617 citations
- The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases (2018) — 6,253 citations
- Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening. (2016) — 918 citations
- Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. (2015) — 1,723 citations
- Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. (2011) — 2,130 citations
- Nonalcoholic fatty liver disease and hepatocellular carcinoma: A weighty connection (2010) — 1,379 citations
- Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease (2008) — 843 citations
- A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. (2006) — 1,769 citations
- Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis (2003) — 725 citations